Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ComboFS versus Seretide Diskus in adults with asthma
2019-004429-26Phase 3Terminated
- Sponsor
- Lek-AM
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of salmeterol + fluticasone in asthma (2 arms), sponsored by Lek-AM. Primary endpoints: Change from baseline in FEV1 at day 56 and day 112 and Baseline-adjusted serial FEV1 AUC0-12 hours on first day of treatment. Started Mar 2020; status: terminated.
02
Drugs
salmeterol + fluticasone
03
Conditions
asthma
Beyond the preview
Go deeper on 2019-004429-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004429-26.